1.Fumonisin B1-Induced Toxicity Was Not Exacerbated in Glutathione Peroxidase-1/Catalase Double Knock Out Mice
Taddesse YAYEH ; Ha Ram JEONG ; Yoon Soo PARK ; Sohyeon MOON ; Bongjun SUR ; Hwan-Soo YOO ; Seikwan OH
Biomolecules & Therapeutics 2021;29(1):52-57
Fumonisin B1 (FB1) structurally resembles sphingolipids and interferes with their metabolism leading to sphingolipid dysregulation. We questioned if FB1 could exacerbate liver or kidney toxicities in glutathione peroxidase 1 (Gpx1) and catalase (Cat) knockout mice. While higher serum levels of thiobarbituric acid reactive substances (TBARS) and sphinganine (Sa) were measured in Gpx1/Cat knockout mice (Gpx1/Cat KO) than wild type mice after 5 days of FB1 treatment, serum levels of alanine aminotransferase (ALT), sphingosine-1 phosphate (So-1-P), and sphinganine-1 phosphate (Sa-1-P) were found to be relatively low. Although Sa was highly elevated in Gpx1/Cat KO mice and wild mice, lower levels of So and Sa were found in both the kidney and liver tissues of Gpx/Cat KO mice than wild type mice after FB1 treatment. Paradoxically, FB1-induced cellular apoptosis and necrosis were hastened under oxidative stress in Gpx1/Cat KO mice.
2.Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea
Hye Yeon KIM ; Jisoo PARK ; Seok Joo MOON ; Sohyeon JEONG ; Jin Hwa HONG ; Jae Kwan LEE ; Geum Joon CHO ; Hyun-Woong CHO
Cancer Research and Treatment 2024;56(1):143-148
Purpose:
BRCA1/2 mutations are well-known risk factors for breast and ovarian cancers in women. Risk-reducing salpingo-oophorectomy (RRSO) is the standard treatment for preventing ovarian cancer with BRCA mutations. Postmenopausal syndrome (symptoms after RRSO can be alleviated by hormone replacement therapy (HRT); however, the use of HRT in carriers of BRCA mutations has been controversial because of the concern that HRT increases the risk of breast cancer. This study aimed to evaluate the effects of HRT in BRCA mutation carriers who underwent RRSO.
Materials and Methods:
A total of 151 carriers, who underwent RRSO between 2013 and 2020 after the diagnosis of BRCA1 or BRCA2 mutations were selected and followed up for a median of 3.03 years. Patients were divided into two groups: those who received HRT after RRSO (n=33) and those who did not (n=118). We compared the incidence of breast cancer over time between these two groups.
Results:
There was no significant difference in the incidence of breast cancer between women who received HRT and those who did not (p=0.229). Multivariate logistic regression analysis, adjusted for age and parity revealed no significant difference in the risk of breast cancer between these two groups (hazard ratio, 0.312; 95% confidence interval, 0.039 to 2.480; p=0.278).
Conclusion
In this study, we found no relationship between post-RRSO HRT and breast cancer in the population with BRCA mutations. Therefore, healthcare providers may consider the alleviation of symptoms of postmenopausal syndrome through HRT in patients who underwent RRSO.
3.Aggression and Neurotransmitters.
Si Young YU ; Yejee CHOI ; Sangjoon KIM ; Hyeonseok S JEONG ; Jiyoung MA ; Young Hoon KIM ; Sohyeon MOON ; Ilhyang KANG ; Eujin JEONG ; Chae Won SUH ; Kyung Shik SHIN ; Jieun E KIM
Journal of the Korean Society of Biological Psychiatry 2016;23(3):108-115
Aggression and aggressive behaviors, often explained as harmful social interaction with the intention of hurting or inflicting damage upon another, have been considered as an adaptive mechanism from the evolutionary psychological point of view. However, various studies on aggression and aggressive behaviors have been done with psychopathological approach as the extreme aggressive behaviors may harm themselves and others at the same time. Recently, researchers have attempted to explain aggression in terms of neurobiological substrates rather than based on traditional psychopathological and/or behavioral concept. In this regard, there have been findings of differences in neurotransmitters and their receptors, and genetic polymorphisms. In this review article, we provide a brief overview of the literature about seven most frequently reported neurotransmitters including neurohormones (serotonin, norepinephrine, dopamine, gamma-aminobutyric acid, nitric oxide, oxytocin and vasopressin) and an associated enzyme (monoamine oxidase A), which are known to be related with aggression and aggressive behaviors.
Aggression*
;
Dopamine
;
gamma-Aminobutyric Acid
;
Intention
;
Interpersonal Relations
;
Neurobiology
;
Neurotransmitter Agents*
;
Nitric Oxide
;
Norepinephrine
;
Oxidoreductases
;
Oxytocin
;
Polymorphism, Genetic
4.Neurocriminology : A Review on Aggression and Criminal Behaviors Using Brain Imaging.
Si Young YU ; Yejee CHOI ; Sangjoon KIM ; Hyeonseok S JEONG ; Jiyoung MA ; Eujin JEONG ; Sohyeon MOON ; Nicole Y KIM ; Ilhyang KANG ; Young Hoon KIM ; Kyung Shik SHIN ; Jieun E KIM
Journal of the Korean Society of Biological Psychiatry 2016;23(2):57-62
Criminology has been understood within a sociological framework until the emergence of neurocriminology, which describes, understands and predicts criminal behaviors from a neurobiological point of view. Not only using biological factors including genes and hormones to understand criminal behaviors, but also using neuroimaging techniques, the field of neurocriminology aims to delve into both structural and functional differences in the brain of individuals with aggression, antisocial personalities, and even the criminals. Various studies have been conducted based on this idea, however, there still are limitations for the knowledge from these studies to be used in the court. In this review article, we provide an overview of the various research in neurocriminology, and provide insight into the future direction and implication of the field.
Aggression*
;
Antisocial Personality Disorder
;
Biological Factors
;
Brain*
;
Criminal Behavior*
;
Criminals*
;
Criminology
;
Humans
;
Neuroimaging*
;
Neurosciences
5.Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study
Hee Jo HAN ; Seung Woo KIM ; Hyunjin KIM ; Jungmin SO ; Eun-Jae LEE ; Young-Min LIM ; Jung Hwan LEE ; Myung Ah LEE ; Byung-Jo KIM ; Seol-Hee BAEK ; Hyung-Soo LEE ; Eunhee SOHN ; Sooyoung KIM ; Jin-Sung PARK ; Minsung KANG ; Hyung Jun PARK ; Byeol-A YOON ; Jong Kuk KIM ; Hung Youl SEOK ; Sohyeon KIM ; Ju-Hong MIN ; Yeon Hak CHUNG ; Jeong Hee CHO ; Jee-Eun KIM ; Seong-il OH ; Ha Young SHIN
Journal of Korean Medical Science 2024;39(18):e150-
Background:
During the coronavirus disease 2019 (COVID-19) pandemic, patients with myasthenia gravis (MG) were more susceptible to poor outcomes owing to respiratory muscle weakness and immunotherapy. Several studies conducted in the early stages of the COVID-19 pandemic reported higher mortality in patients with MG compared to the general population. This study aimed to investigate the clinical course and prognosis of COVID-19 in patients with MG and to compare these parameters between vaccinated and unvaccinated patients in South Korea.
Methods:
This multicenter, retrospective study, which was conducted at 14 tertiary hospitals in South Korea, reviewed the medical records and identified MG patients who contracted COVID-19 between February 2022 and April 2022. The demographic and clinical characteristics associated with MG and vaccination status were collected. The clinical outcomes of COVID-19 infection and MG were investigated and compared between the vaccinated and unvaccinated patients.
Results:
Ninety-two patients with MG contracted COVID-19 during the study. Nine (9.8%) patients required hospitalization, 4 (4.3%) of whom were admitted to the intensive care unit. Seventy-five of 92 patients were vaccinated before contracting COVID-19 infection, and 17 were not. During the COVID-19 infection, 6 of 17 (35.3%) unvaccinated patients were hospitalized, whereas 3 of 75 (4.0%) vaccinated patients were hospitalized (P < 0.001). The frequencies of ICU admission and mechanical ventilation were significantly lower in the vaccinated patients than in the unvaccinated patients (P = 0.019 and P = 0.032, respectively). The rate of MG deterioration was significantly lower in the vaccinated patients than in the unvaccinated patients (P = 0.041). Logistic regression after weighting revealed that the risk of hospitalization and MG deterioration after COVID-19 infection was significantly lower in the vaccinated patients than in the unvaccinated patients.
Conclusion
This study suggests that the clinical course and prognosis of patients with MG who contracted COVID-19 during the dominance of the omicron variant of COVID-19 may be milder than those at the early phase of the COVID-19 pandemic when vaccination was unavailable. Vaccination may reduce the morbidity of COVID-19 in patients with MG and effectively prevent MG deterioration induced by COVID-19 infection.